clinical trial · NCT06979596
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Merck Sharp & Dohme LLC·phase2·recruiting·n = 250
Malignant NeoplasmOpevesostatFludrocortisone/ Fludrocortisone acetateDexamethasone/Dexamethasone acetateRescue MedicationsFulvestrantExemestaneMegestrol acetate/Medroxyprogesterone acetateTamoxifen
brief summary
Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones. Researchers will compare MK-5684 to the standard treatments for each cancer type in this study. The goal of this study is to learn if people who receive MK-5684 live longer without the cancer growing or spreading compared to people who receive a standard treatment.
started
Aug 11, 2025
primary completion
Nov 4, 2027
completion
Nov 4, 2027
last updated
Apr 13, 2026
official title
A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol